drugset / Trial / NCT01416428
Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD), activity, and safety of oprozomib in patients with hematologic malignancies.
Timeline
- Start
- 2011-10-15
- Primary completion
- 2016-08-08
- Completion
- 2019-08-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oprozomib | Small molecule | — | Oral |